A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases by Makhlouf, Hoda A. et al.
ORIGINAL ARTICLE
A prospective study of antituberculous drug-induced
hepatotoxicity in an area endemic for liver diseases
Hoda A. Makhlouf Æ Ahmed Helmy Æ
Ehab Fawzy Æ Madiha El-Attar Æ Hebat Alla G. Rashed
Received: 1 February 2008/Accepted: 19 June 2008/Published online: 25 July 2008
 Asian Paciﬁc Association for the Study of the Liver 2008
Abstract
Purpose Identiﬁcation of risk factors associated with
antituberculosis drug-induced hepatotoxicity (anti-TB-
DIH) is important, especially in endemic area for TB and
liver disease. This study assessed the incidence and risk
factors of anti-TB-DIH in upper Egyptian patients treated
for active pulmonary and extra-pulmonary TB.
Methods A total of 100 consecutive TB patients were
prospectively followed up both clinically and biochemi-
cally before and during their course of anti-TB therapy
with daily doses of isoniazid, rifampin, ethambutol, and
pyrazinamide, or streptomycin.
Results Anti-TB-DIH developed in 15 (15%) patients
within 15–60 days (median: 30 days) from the onset of ther-
apy. Liver function normalized in 10 (60%) patients within 2
weeks from cessation of therapy. No recurrence of DIH was
observed after reintroduction of therapy. Only 1 patient died
from fulminant hepatic failure despite discontinuation of
all anti-TB drugs. By univariate analysis, patients with anti-
TB-DIH had more pre-existing liver disease (P = 0.024; OR:
3.60; 95% CI: 1.16–11.18), lower body mass index (BMI;
P = 0.037; OR: 3.73; 95% CI: 1.04–10.56), lower serum
albumin(P=0.035;OR:3.31;95%CI:1.04–10.56),andmore
extensive disease (P = 0.033; OR: 3.50; 95% CI: 1.11–11).
Age,gender,raisedbaselinetransaminaseslevel,inclusionof
pyrazinamide, and inactive hepatitisB orC carrier state were
not signiﬁcant risk factors of DIH. Using multivariate
regression analysis, only pre-existing liver disease and lower
BMI of 20 kg/m
2 or less were independent predictors of DIH
(P = 0.024 and P =0 . 0 4 7 ,r e s p e c t i v e l y ) .
Conclusion Anti-TB-DIH is not uncommon, needs early
recognition and treatment, and is more in patients with pre-
existing liver disease and low BMI.
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Tuberculosis (TB) is endemic in developing countries,
including Egypt, and is increasingly recognized in developed
countries, especially in immune-compromised patients [1].
Despite the efﬁcacy of anti-TB agents, hepatotoxicity from
ﬁrst-line drugs—isoniazid (INH), rifampin (RIF), and pyra-
zinamide (PZA)—may result in drug(s) discontinuation, de
novoliverdisease,orexacerbationofpre-existingones[2–6].
Anti-TB drug-induced hepatotoxicity (DIH) ranges from
nonspeciﬁctransaminasitis tofulminanthepaticfailure[5,6].
The exact factors associated with anti-TB-DIH are
unknown. However, alcohol abuse, increasing age, pre-
existing liver disease, slow acetylators, and severe malnu-
trition have been reported as risk factors [4, 7]. Recent
studies suggested that polymorphism and reduced activity
of hepatic N-acetyl-transferase-2 genes and glutathione-
S-transferase contribute to DIH [8].
The incidence, pattern, and predictors of anti-TB-DIH
have not been prospectively studied before in Egypt, where
chronic liver diseases secondary to hepatitis B virus (HBV)
and hepatitis C virus (HCV) infections and/or schistoso-
miasis are prevalent. Anti-TB-DIH in such endemic areas
is difﬁcult to evaluate and need to be differentiated from
exacerbation of pre-existing diseases and from de novo
infections. Therefore, the aims of this study were to
determine the incidence and pattern of anti-TB-DIH in
patients with active pulmonary and extra-pulmonary TB
and to assess the independent risk factors associated with
DIH in these patients.
Patients and methods
Patients
This prospective study was conducted in the Chest Out-
patient Clinic, Assiut University Hospital, Assiut, Egypt,
from October 8, 2004, till January 4, 2005. Inclusion cri-
teria comprised patients with active pulmonary or extra-
pulmonary TB, who were going to start anti-TB drug
regimen irrespective of their liver disease status. Of 104
consecutive patients registered in the clinic during the
study period, 4 patients did not complete their follow-up
and were excluded. All patients gave written informed
consent and the study was approved by the Faculty of
Medicine Research Ethics Committee.
Anti-TB regimen
Total treatment period was 6 months including intensive
and continuation phases (2 and 4 months, respectively).
The intensive phase comprised INH (5 mg/kg day
-1;
maximum 300 mg/day), RIF (10 mg/kg day
-1; maximum
600 mg/day), EMB (15–20 mg/kg day
-1), and PZA (20–25
mg/kg day
-1), or streptomycin. The continuation phase
comprised daily similar doses of INH and RIF.
Diagnosis of DIH
Anti-TB-DIH was diagnosed according to International
UnionagainstTuberculosisandLungDisease[9]asfollows:
1. Normalization of liver enzymes and resolution of signs
and symptoms of hepatotoxicity after withdrawal of all
anti-TB drugs, and
2. Presence of at least one of the following:
i. A rise to more than 2 the upper limit of normal
(ULN) level of alanine transaminase (ALT) and/or
aspartate transaminase (AST) [10–12].
ii. A rise in total serum bilirubin to more than 1.5
mg/dl.
iii. Any increase in AST and/or ALT above pretreat-
ment levels together with anorexia, nausea,
vomiting, and jaundice.
Baseline assessment
Pretreatment evaluation included clinical history, physical
examination, body mass index (BMI = body weight (kg)/
[height (m)]
2), chest radiographs, abdominal ultrasonog-
raphy, complete blood cell count, liver function tests
(LFTs), and hepatitis markers. Samples from HBsAg, anti-
HB core antibody (anti-HBc), and/or anti-HCV antibody-
positive patients were tested for HBV DNA and HCV
RNA, respectively. A BMI of less than 20 kg/m
2 was
considered as low. Hypoalbuminemia was deﬁned as serum
albumin level of less than 3.5 mg/dl. The ULN in our
laboratory is 41 IU/l for ALT and 38 IU/l for AST.
Follow-up
Patients were followed closely in a specialized clinic by a
chest physician and a hepatologist fortnightly over the ﬁrst
2 months, then monthly till the end of the 6-month period.
In each visit, patients were assessed clinically (response to
therapy, any adverse effects, and nutritional status), and
biochemically including LFTs, which were repeated
whenever symptoms or signs suggestive of hepatotoxicity
(nausea, anorexia, malaise, vomiting, hepatomegaly, or
jaundice) occur.
Exclusion of other causes of liver disease
Before attributing hepatotoxicity to anti-TB drugs, other
causes of liver diseases were excluded by: IgM anti-
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123hepatitis A virus antibody, HBsAg, IgM anti-HBc in
addition to the HBV DNA if the HBsAg and/or HBcAb are
positive, anti-HCV antibody and HCV RNA if the anti-
HCV antibody is positive, autoimmune screen (anti-nuclear
and anti-smooth muscle antibodies), and abdominal ultra-
sound to asses for liver abscesses, focal lesions, or biliary
obstruction.
Management of DIH
INH, RIF, and PZA were stopped immediately in all
patients who developed anti-TB-DIH when serum trans-
aminases levels were more than 3 times the ULN in the
presence of symptoms or more than 5 times the ULN with
or without symptoms. LFTs were monitored weekly for 2
weeks, and then fortnightly. Two other anti-TB medica-
tions without hepatotoxicity, namely, EMB and
streptomycin, were used until the cause of the hepatitis is
identiﬁed. Anti-TB medications (INH, RIF, and PZA) were
restarted once transaminases levels return back to less than
2 times the ULN. In patients with elevated baseline
transaminases from pre-existing liver disease, drugs were
restarted when the enzymes return to baseline levels. Anti-
TB drugs were reintroduced with RIF, followed by INH,
and then PZA as previously reported [13]. If a patient again
develops hepatotoxicity, the causative drug was perma-
nently discontinued [14].
Statistical analysis
Data were collected in a specialized Data Collection Form,
and then entered in the Statistical Package for Social Sci-
ences (SPSS, version 15.0; SPSS Inc., Chicago, IL) for
Windows. Data are expressed as mean ± SD and fre-
quencies as appropriate. Data were compared through
Student’s t test and v
2 analysis for continuous variables and
proportions, respectively. Elevations in serum AST and
ALT levels (pretreatment levels vs. peak levels during
treatment) were analyzed by paired t test. Risk factors for
DIH were evaluated by multivariate logistic regression
analyses. Statistical signiﬁcance was accepted at P\0.05.
Results
Baseline patients’ characteristics are shown in Table 1. One
hundred patients were included in this prospective study, 44
(44%) male and 56 (56%) females, with mean ± SD age
33.60 ± 13.03 years. The mean ± SD BMI was 20.29 ±
4.38 kg/m
2. A total of 37 (37%) patients had active pul-
monary TB and 63 (63%) patients had active extra-
pulmonary TB. As shown in Table 2, extra-pulmonary TB
involved the pleura in 23 patients (23%), lymph node in 20
patients (20%), the peritoneum in 16 patients (16%), and
other sites in the remaining 4 patients (4%).
During the study period, anti-TB-DIH was detected
clinically and conﬁrmed biochemically in 15 patients
(15%; Fig. 1). The time interval from onset of therapy and
the detection of hepatotoxicity ranged from 15 to 60 days
(median: 30 days). Twelve patients had alteration in LFTs
within 2–4 weeks, whereas the rest (n = 3) showed alter-
ation after 2 months of treatment. The time interval from
the onset of hepatotoxicity to normalization of LFTs was
15–45 days (median: 15 days). Almost 60% of patients had
normalization of their LFTs within 2 weeks of cessation of
anti-TB therapy.
The clinical manifestations of DIH were nausea, anor-
exia, and malaise in 10 (66.7%) patients, vomiting in 2
(13.3%) patients, jaundice in 5 (33.3%) patients, and
encephalopathy in 1 (6.7%) patient (Table 3). Anti-TB
therapy was stopped temporarily until their clinical and
biochemical proﬁles normalized. None of the patients had
recurrence of hepatotoxicity with the reintroduction of anti-
TB drugs.
Death was reported in 1 case because of fulminant
hepatic failure that developed 3 weeks after the onset of
therapy. This case belonged to a 21-year-old woman with
pulmonary TB and positive serology for HCV. Her BMI
was 17.53 kg/m
2 and she was on INH, RIF, PZA, and
streptomycin. Her hepatic failure progressed till she died 3
weeks later despite discontinuation of all her anti-TB drugs
and supportive measures; liver transplantation was not
feasible.
Administration of anti-TB drugs lead to slight, but sta-
tistically signiﬁcant, elevations in transaminases levels in
all patients (n = 100; P = 0.02 for ALT and P = 0.00 for
AST). All patients developing DIH (n = 15) showed sig-
niﬁcant rise in ALT and AST levels, which did not exceed
5 times the ULN in all of them. A rise in bilirubin level was
detected in 7 patients only, 4 of them had increase of more
than 3 mg/dl (Table 4).
There was no statistically signiﬁcant difference in the
incidence of DIH between patients with pulmonary TB and
those with extra-pulmonary TB (Table 2). However,
patients with pre-existing liver disease (liver cirrhosis, fatty
liver, or diffuse hepatic pathology) were found to be at
higher risk for anti-TB-DIH (P = 0.024; OR: 3.60; 95% CI:
1.16–11.18; Table 4). Also, patients with BMI of less than
20 kg/m
2 (P = 0.037; OR: 3.73; 95% CI: 1.04–10.56) and
those with serum albumin levels of less than 3.5 mg/dl (P =
0.035; OR: 3.31; 95% CI: 1.04–10.56) were found to be at
higher risk for anti-TB-DIH. Seven of the ﬁfteen patients
who developed DIH had positive sputum smear for acid-
fast bacilli, which may indicate that open pulmonary TB
has a probable role in predisposing the patient to DIH (P =
0.033; OR: 3.50; 95% CI: 1.11–11; Table 5). In the
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123Table 1 Baseline patients’ characteristics
a
Variable All patients (n = 100) Patients without DIH (n = 85) Patients with DIH (n = 15)
Mean age, years 33.60 ± 13.03 33.16 ± 13.12 36.07 ± 12.69
Gender
Men 44 (44%) 48 (56.5%) 37 (43.5%)
Women 56 (56%) 8 (35.3%) 7 (46.7%)
Height, m 162.87 ± 9.73 162.67 ± 9.71 164 ± 10.8
Weight, kg 53.61 ± 11.19 54.12 ± 11.05 50.73 ± 11.97
BMI, kg/m
2 20.29 ± 4.38 20.54 ± 4.37 18.88 ± 4.30
Albumin, g/l 36.57 ± 7.59 37. 33 ± 7.44 37. 33 ± 7.44
b
Bilirubin, lmol/l 7.42 ± 3.87 7.14 ± 4.04 7.81 ± 2.71
ALT, U/l 17.27 ± 12.38 17.53 ± 13.15 15.87 ± 6.73
AST, U/l 28.50 ± 14.89 28.78 ± 15.44 27 ± 11.67
Note: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DIH, drug-induced hepatotoxicity; n = number
a Data expressed as mean ± SD except gender (number (percentage))
b P\0.05 as compared with non-DIH group
Table 2 Hepatotoxicity among patients with different clinical vari-
eties of tuberculosis
a
Clinical variety Varieties of tuberculosis Hepatotoxicity
n % n %
Pulmonary 37 37 8 21.6
Pleural effusion 23 23 4 17.4
Lymph node 20 20 0 0
Abdominal 16 16 2 12.5
Peritonial 14 14 1 7.1
Intestinal 2 2 1 50
Pericardial 1 2 0 0
Genital 2 1 0 0
Cutaneous 1 1 1 100
a P = 0.08 by v
2 analysis when compared with drug-induced hepa-
totoxicity in patients with pulmonary TB (n = 37) versus those with
extra-pulmonary TB (n = 67)
15%
85%
Yes
No
Fig. 1 Incidence of anti-TB drug-induced hepatotoxicity in patients
with tuberculosis (n = 100)
Table 3 Clinical presentations of anti-TB DIH
Variable Patients with anti-TB-DIH (N = 15)
n %
Nausea 10 66.7
Anorexia 10 66.7
Malaise 10 66.7
Vomiting 2 13.3
Jaundice 5 33.3
Encephalopathy 1 6.7
Note: n, number; DIH, drug-induced hepatotoxicity
Table 4 Alterations in liver function tests in the patients who
developed anti-TB DIH
Variable Patients with anti-TB DIH (N = 15)
n %
ALT in all the 15 cases
B3 times ULN 9 60.00
3–4 times ULN 4 26.67
[4 times ULN 2 13.33
AST in all the 15 cases
B3 times ULN 8 53.33
3–4 times ULN 6 40.00
[4 times ULN 1 6.67
Raised bilirubin in 7 cases
1.5–2 mg/dl 2 28.57
2–3 mg/dl 1 14.29
[3 mg/dl 4 57.14
Note: ULN, upper limit of normal; n, number; DIH, drug-induced
hepatotoxicity; ALT, alanine aminotransferase; AST, aspartate
aminotransferase
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123multivariate logistic regression analysis, only pre-existing
liver disease (P = 0.024; OR: 0.259; 95% CI: 0.08–0.83)
and BMI less than 20 kg/m
2 (P = 0.047; OR: 0.25; 95% CI:
0.63–0.98) were found to be independent predictors of anti-
TB-DIH (Table 6).
As shown in Table 5, there was no signiﬁcant difference
between patients who developed DIH and those who did not
regarding other variables, such as age, sex, and raised
baselineAST, ALT,orthe inclusion ofPZA inthe treatment
regimen.WhileinactiveHBVcarrierswerenotfoundtobeat
a higher risk for anti-TB-DIH, inactive HCV carriers appear
at a higher risk although it did not reach statistical signiﬁ-
cance (P = 0.088; OR: 3.07; 95% CI: 0.81–11.69).
Table 5 Risk factors for anti-
TB drug-induced hepatotoxicity
by univariate analysis
Note: OR, odds ratio; CI,
conﬁdence interval
a HCV infection was deﬁned as
positive serum anti-HCV
antibody and HCV RNA by
polymerase chain reaction
b HBV infection was deﬁned as
positive serum hepatitis B
surface antigen and HBV DNA
by polymerase chain reaction
Variables Hepatotoxicity OR 95% CI P
n Rate, %
Gender 0.88 0.29–2.65 0.821
Men (n = 44) 7 15.9
Women (n = 56) 8 14.3
Age 1.29 0.42–3.97 0.434
[35 years (n = 65) 6 13.8
B35 years (n = 35) 9 17.1
Albumin level, g/dl 3.31 1.04–10.56 0.035
C3.5 (n = 58) 5 8.6
\3.5 (n = 42) 10 23.8
Body mass index, kg/m
2 3.73 1.04–10.56 0.037
C20 (n = 44) 3 8.6
\20 (n = 56) 12 21.4
Pre-existing liver disease 3.60 1.16–11.18 0.024
No (n = 66) 6 9.1
Yes (n = 44) 9 26.5
Hepatitis C virus
a 3.07 0.81–11.69 0.088
Negative (n = 87) 11 12.6
Positive (n = 13) 4 30.8
Hepatitis B virus
b 0.85 0.78–0.92 0.611
Negative (n = 97) 15 15.5
Positive (n =3 ) 0 0
Abnormal baseline transaminases 0.48 0.06–4.03 0.430
No (n = 88) 14 15.9
Yes (n = 12) 1 8.3
Acid-fast bacilli in sputum 3.50 1.11–11.00 0.033
Negative (n = 67) 8 10.5
Positive (n = 24) 7 29.2
Severity of disease 0.37 0.07–1.85 0.201
Minimal (n = 15) 5 31.3
Moderate/advanced (n = 21) 3 14.3
Use of pyrazinamide 0.97 0.28–3.33 0.587
No (n = 26) 4 15.4
Yes (n = 74) 11 14.9
Table 6 Independent risk factors for anti-TB drug-induced hepato-
toxicity by multivariate analysis
Variables Hepatotoxicity OR 95% CI P
n Rate, %
Body mass index, kg/m
2 0.25 0.03–0.98 0.047
C20 (n = 44) 3 8.6
\20 (n = 56) 12 21.4
Pre-existing liver disease 0.26 0.08–0.83 0.024
No (n = 66) 6 9.1
Yes (n = 44) 9 26.5
Note: OR, odds ratio; CI, conﬁdence interval; n, number
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The use of multidrug regimens for the treatment of TB,
such as the combination of INH, RIF, and PZA, has been
associated with an increased incidence of hepatotoxicity
when compared with INH monotherapy used for anti-TB
prophylaxis [5, 15]. The incidence of anti-TB-DIH varies
worldwide and has been reported to be higher in devel-
oping countries where factors such as acute or chronic liver
disease, indiscriminate use of drugs, malnutrition, and
more advanced TB have been implicated [16–18]. How-
ever, it is unclear if these are independent risk factors for
hepatotoxicity. In our study, 15% of the patients developed
anti-TB-DIH, an incidence similar to reports from Asia
(8.0–19.8%) [14, 19–21], and higher than those from the
West (4.3%) [22].
The variation in the incidence of anti-TB-DIH may be
related to differences in patients’ characteristics, regimens
used,type ofmonitoring, andthe diagnosticcriteriadeﬁning
hepatotoxicity [23]. Despite these variations, the issue of
anti-TB DIH remains important, especially in countries that
are endemic for both TB and liver diseases as the case in
Africa, Asia,andSouthAmerica,andisexpectedtoincrease
inthedeveloped countrieswiththewell-knownriseofTBin
the era of immunosuppressive therapy.
Anti-TB-DIH in our patients manifested as anorexia,
nausea, vomiting, and jaundice, and occurred 15–60 days
(median: 30 days) after initiation of therapy. This was in
agreement with the results of Shakya et al. [20], who
reported an interval of 12–60 days (median: 28 days).
Similarly, Mahmood et al. [14] reported that the onset of
anti-TB-DIH in almost two thirds of their patients (41/67)
was within 14 days from the start of therapy. This
emphasizes the importance of close and more frequent
monitoring of patients in the ﬁrst 2 months of anti-TB
therapy.
In the present study, the interval from the onset of
hepatotoxicity to LFTs normalization was 15–45 days
(median: 15 days). In almost three ﬁfths of patients, their
LFTs normalized within 2 weeks. Also, Mahmood et al.
[14] reported that in four ﬁfths of patients, their LFTs
normalized within 2 weeks. In addition, Shakya et al. [20]
reported that liver enzymes returned to the normal level
within few days of cessation of therapy.
Several studies suggested that increasing age is a
potential risk factor for anti-TB-DIH [14, 21, 24–28]. One
study reported that the rate of anti-TB-DIH ranges from 2
to 8% as age increases, with an average of 5% [28]. Other
studies reported that hepatotoxicity ranges from 22 to 33%
in patients older than 35 years compared with a range from
8 to 17% in those younger than 35 years [21, 29]. Also,
Mahmood et al. [14] reported that older age group was
affected more than the younger age group (25.8 and 14.4%,
respectively). In contrast, Shakya et al. [20] reported that
the incidence of anti-TB-DIH is higher in younger patients.
This might be explained by the fact that the majority of
patients enrolled in their study were young. This study and
others [30] have showed that age is not a risk factor for the
development of anti-TB-DIH.
Several studies reported that females are at increased
risk of hepatotoxicity compared with males [24, 25, 31,
32]. However, this difference was not treatment limiting,
nor statistically signiﬁcant [31, 32]. One study did show a
4-fold increase in the risk of treatment-limiting hepato-
toxicity in women, but with an overall incidence of only
2% [25]. Mahmood et al. [14] reported higher incidence of
anti-TB-DIH in females than males (26.3% vs. 19.7%). The
higher vulnerability of females could be due to variations
in pharmacokinetics and slower acetylation pattern [33]
and/or lower BMI. Other studies, in agreement with ours,
showed no increased risk of anti-TB-DIH in women [3, 27,
30, 34–36].
Malnutrition may be a risk factor for anti-TB-DIH as
detected by BMI of less than 20 kg/m
2 and serum albumin
levels of less than 3.5 mg/dl. This may be due to depletion
of glutathione stores, which makes patients more vulnera-
ble to oxidative injuries, and the slower pace at which their
livers metabolize drugs. Indeed, low BMI and hypoalbu-
minemia were associated with higher rates of anti-TB-DIH
in several studies [14, 16, 20, 28, 37–39].
Seven of the ﬁfteen patients who had anti-TB-DIH in
this study had positive sputum smear for acid-fast bacilli.
This was also reported in another study in which 40
(59.7%) patients were sputum smear positive and were
more severely affected [14], indicating that patients with
more extensive or open pulmonary TB are at an increased
risk for anti-TB-DIH, necessitating more frequent and
closer follow-up.
Inclusion of PZA in the regimen did not lead to more
hepatotoxicity in our patients. This is consistent with earlier
reports [17, 34, 40] and clinical trials [41, 42]. Some studies
[6, 43, 44], on the other hand, have indicated that the inci-
dence of PZA-induced hepatotoxicity was signiﬁcantly
higher than that observed with the other ﬁrst-line drugs.
Similartotheresultofothers[3,7],wefoundthatpatients
with pre-existing liver disease are at higher risk of anti-TB-
DIH. Indeed, an increased risk of hepatotoxicity during
treatment of TB was observed in patients with abnormal
baseline transaminases [45]. In the current study, inactive
HBV carrier state was not a risk factor for anti-TB-DIH.
However, our study included only 3 inactive HBV carriers.
Previous studiesshowedmoreanti-TB-DIHinHBVcarriers
[34, 46, 47], whereas 1 did not [48]. Also, we observed a
trend toward more anti-TB-DIH in inactive HCV carriers,
although it did not reach statistical signiﬁcance. A study on
has 128 inpatients in Florida, approximately 30% of HCV-
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11% among uninfected individuals, and hepatitis C was an
independent risk factor for the development of hepatotox-
icity [49].
In our study, a 21-year-old woman died secondary to
fulminant hepatic failure despite discontinuation of all anti-
TB drugs. It has been suggested that the severity of INH-
induced hepatotoxicity may be worse or even fatal in
women [11, 50]. Liver transplantation was the deﬁnitive
therapy, but unfortunately was not available.
In conclusion, anti-TB-DIH is not uncommon, can be
fatal, and is signiﬁcantly more frequent in patients with
pre-existing liver disease, malnourished patients, and those
with hypoalbuminemia. Also, extensive or open pulmonary
TB may have a role in predisposing patient to hepatotox-
icity. Close follow-up, early recognition, and the
immediate withdrawal of the causative agent are essential
to prevent progression and allow the liver to heal. This
topic is of higher importance in the developing countries
where both TB and liver diseases are endemic.
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